External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease

Published:2018-02 Issue:1 Volume:40 Page:120-129
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Santacana Eugènia,Rodríguez-Alonso Lorena,Padullés Ariadna,Guardiola Jordi,Rodríguez-Moranta Francisco,Serra Katja,Bas Jordi,Morandeira, Biology Francisco,Colom Helena,Padullés Núria

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents;Hanauer;Inflamm Bowel Dis.,2010

2. Optimizing anti-TNF treatments in inflammatory bowel disease;Ben-Horin;Autoimmun Rev.,2014

3. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy;Danese;Aliment Pharmacol Ther.,2011

4. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort;Schnitzler;Gut.,2009

5. Review article: loss of response to anti-TNF treatments in Crohn's disease;Ben-Horin;Aliment Pharmacol Ther.,2011

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models?;European Journal of Drug Metabolism and Pharmacokinetics;2024-05-05

2. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17

3. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model;Pediatric Drugs;2024-03-20

4. Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease;Therapeutic Drug Monitoring;2023-02-23

5. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review;Pharmaceutics;2022-09-30